133 related articles for article (PubMed ID: 646674)
21. [The outlook for the management of endometrial hyperplasia. A preliminary report].
Martínez-Meza MT; Sojo-Aranda I; Santiago-Payán H; González-Diddi M; Cortés-Gallegos V
Ginecol Obstet Mex; 1987 Mar; 55():80-4. PubMed ID: 3154367
[No Abstract] [Full Text] [Related]
22. Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia.
Bitto A; Granese R; Triolo O; Villari D; Maisano D; Giordano D; Altavilla D; Marini H; Adamo EB; Nicotina PA; D'Anna R; Squadrito F
Phytomedicine; 2010 Sep; 17(11):844-50. PubMed ID: 20570122
[TBL] [Abstract][Full Text] [Related]
23. [Use of 19-nor-17 alpha-hydroxyprogesterone caproate in endometrial cancer].
Márquez J; Dabancens A; González O; Rosmanich A
Rev Chil Obstet Ginecol; 1976; 41(5):304-11. PubMed ID: 1030512
[No Abstract] [Full Text] [Related]
24. [Clinicopathological analysis in cases with glandular and atypical glandular hyperplasia treated with gestagens].
Ivanov S
Akush Ginekol (Sofiia); 2005; 44(4):18-20. PubMed ID: 16028373
[TBL] [Abstract][Full Text] [Related]
25. [Effect of synthetic progestins on the content of sex chromatin in endometrial hyperplasia].
Rotkina IE; Lutsik LA
Akush Ginekol (Mosk); 1977 Jul; (7):33-5. PubMed ID: 900404
[No Abstract] [Full Text] [Related]
26. Danazol reverses endometrial hyperplasia to normal endometrium.
Bulletti C; Jasonni VM; Tabanelli S; Balducci M; Fuschini G; Flamigni C
Acta Eur Fertil; 1987; 18(3):185-7. PubMed ID: 3439404
[TBL] [Abstract][Full Text] [Related]
27. Immunohistological localisation of vascular endothelial growth factor in human endometrium.
Naresh B; Sengupta J; Bhargava V; Kinra G; Hu J; Ghosh D
Indian J Physiol Pharmacol; 1999 Apr; 43(2):165-70. PubMed ID: 10365307
[TBL] [Abstract][Full Text] [Related]
28. [Changes in the endometrial proliferative processes under the influence of progesterone and norethisterone in an organ culture].
Zheleznov BI; Beliaeva LA
Akush Ginekol (Mosk); 1980 Mar; (3):32-5. PubMed ID: 7377496
[No Abstract] [Full Text] [Related]
29. Endometrial ablation. A report of four cases.
Gimpelson RJ; Lentz RD
J Reprod Med; 1993 Aug; 38(8):592-4. PubMed ID: 8410862
[TBL] [Abstract][Full Text] [Related]
30. [Planning of the treatment of atypical hyperplasia of the endometrium in patients with uterine myoma].
Tkeshelashvili VT; Bokhman IaV; Vishnevskiĭ AS
Vopr Onkol; 1984; 30(3):71-6. PubMed ID: 6201002
[TBL] [Abstract][Full Text] [Related]
31. Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma.
Hamid AA; Mandai M; Konishi I; Nanbu K; Tsuruta Y; Kusakari T; Kariya M; Kita M; Fujii S
Cancer; 2002 Feb; 94(4):997-1005. PubMed ID: 11920468
[TBL] [Abstract][Full Text] [Related]
32. Postmenopausal uterine bleeding of nonorganic cause.
Choo YC; Mak KC; Hsu C; Wong TS; Ma HK
Obstet Gynecol; 1985 Aug; 66(2):225-8. PubMed ID: 4022485
[TBL] [Abstract][Full Text] [Related]
33. [Effects of tamoxifen and oxyprogesterone caproate on steroid hormone receptors in tumors and indicators of reproductive homeostasis in patients with cancer of the uterine body].
Vishnevskiĭ AS; Bokhman IaV; Tsyrlina EV; Bobrov IuF; Shtofmakher IA
Akush Ginekol (Mosk); 1988 Nov; (11):33-6. PubMed ID: 3239679
[No Abstract] [Full Text] [Related]
34. [Surgical treatment of precancer and cancer of endometrium].
Ivanov S; Khadzhiolov N; Batashki I
Akush Ginekol (Sofiia); 2007; 46(6):12-4. PubMed ID: 17974165
[TBL] [Abstract][Full Text] [Related]
35. Hormonal pathology of the endometrium.
Deligdisch L
Mod Pathol; 2000 Mar; 13(3):285-94. PubMed ID: 10757339
[TBL] [Abstract][Full Text] [Related]
36. The use of GnRH agonists depot for the treatment of dysfunctional uterine bleeding.
Colacurci N; De Placido G; Galasso M; Mollo A; Perino A; Cittadini E
Acta Eur Fertil; 1991; 22(4):229-31. PubMed ID: 1844328
[TBL] [Abstract][Full Text] [Related]
37. [Cystic glandular hyperplasia of endometrium associated with intramural adenomyosis - singular results following progestational therapy].
Mazzarella A; Ventura T; Sindici G
Boll Soc Ital Biol Sper; 1980 Aug; 56(15):1567-73. PubMed ID: 7459076
[TBL] [Abstract][Full Text] [Related]
38. [Histogenesis of uterine corpus carcinoma--relation to atypical endometrial hyperplasia].
Moriwaki S; Yamamoto Y; Takashima S; Hiasa T; Masaoka H; Chiba T; Yokoyama T; Hiura M
Gan No Rinsho; 1984 Oct; 30(13):1686-92. PubMed ID: 6513022
[TBL] [Abstract][Full Text] [Related]
39. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
